Sinopharm plots more M&A; Mitsubishi Tanabe recalls 3 injectable drugs;

 @FiercePharma: Steve Jobs might benefit from new cancer drugs. Report | Follow @FiercePharma

> Sinopharm, China's biggest drug distributor, plans to spend at least ¥5 billion ($759 million) buying companies in the next two years after agreeing to its largest acquisition since going public. Story

> Savient Pharmaceuticals named former Eli Lilly oncology executive John Johnson as its chief executive effective Jan. 31. Report

> John Horan, who served as chairman and CEO of Merck from 1976 to 1985 as the company grew to become the world's largest drugmaker, has died. He was 90. Item

> Mylan said it settled a patent dispute with Pfizer, which will enable it to sell the generic version of the blood pressure drug Caduet beginning Nov. 30. News

> Mitsubishi Tanabe Pharma said it will recall 2 million shots of three injected drugs made at a factory in Japan after an employee failed to test the medicines properly to ensure they met quality controls. Article

> Genzyme has voluntarily repaid $6 million in job-creation incentives to Massachusetts after failing to meet their terms. Report

> Bristol-Myers Squibb, which spent $885 million to acquire Seattle-based ZymoGenetics in October, has decided to maintain its presence there. Report

> The cost of Johnson & Johnson's string of recent McNeil product recalls, most notably those of children's medicines: about $900 million in lost sales in 2010. Item

> Most Americans do not want Congress to block funding for various new healthcare measures even as the nation remains split on the sweeping overhaul passed last year, a new poll found. Story

> Irish drugmaker Elan has quietly laid off 130 people, or about 10 percent of its workforce. Article

Biotech News

 @FierceBiotech: Rogosin investigators use cancer to fight cancer. Item | Follow @FierceBiotech

 @JohnCFierce: FYI, I'm headed to NY Feb 14-16 for the BIO investor forum; Milan for Bio-Europe March 14-16, sandwiched between a couple of webinars. Follow @JohnCFierce

> Data vs. market "exclusivity" in blockbuster scrap over biosimilars. Story

> Report: Elan chops San Francisco R&D in big shakeup. Item 

> Sanofi's Viehbacher cites "progress" in takeover talks with Genzyme. Article 

> Abbott chops 1,900 workers after experimental drugs flop. News 

Drug Delivery News

> FDA issues guidance on maximum 'sprinkle drug' bead size. Story 

> NanoPopcorn targets, cooks and tracks prostate cancer cells. Item

> Pacira licenses DepoFoam to Novo Nordisk, plans IPO. Article 

> Government funding makes sense for early pharma research. Report 

> Nano in the brain: Is it safe? Story

Medical Device News

> 3M, beleagured J&J, announce financial results. Story 

> Abbott stent sales soar in Q4. Article 

> CSA Medical snares $10M in first round. Story 

> Abbott to ask FDA panel for expanded approval of carotid stent. News 

> Stryker eyeing acquisitions. Report 

> Shamed cardiologist's suit against med center transferred. Article 

And Finally... German Health Minister Philipp Rösler sent a letter to the nation's drugmakers, asking them to refuse any requests from the U.S. for the drug sodium thiopental, which is used in lethal injections. News

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.